Ranbaxy

Ranbaxy transfers R&D unit to Daiichi Sankyo

Daiichi Sankyo

Daiichi Sankyo of Japan had been given the research division of Ranbaxy Laboratories for new drugs as part of an ongoing integration programme. Ranbaxy has now become a pure generic drug maker.

The Indian company will hold back its research activity for its anti-malarial new drug which is currently in Phase-III trials besides those molecules which are in advanced stages of development and those being developed in partnership with UK’s drug company GlaxoSmithKline. Ranbaxy did not provide financial details of the transaction.

Ranbaxy Laboratories nets Rs 963 cr in Q1in 2010 twice, retains profit guidance

Ranbaxy Laboratories nets Rs 963 cr in Q1in 2010 twice, retains profit guidance

Even as it reported a bottom-line twice that in the first three months ended, India’s largest drug maker, Ranbaxy Laboratories, has reported that it expects a net profit of Rs 460 crore in 2010. The Revenue during the quarter soared

Ranbaxy Recorded Profit in Forth Quater

Ranbaxy Recorded Profit in Forth Quater

India’s largest drug manufacturer, Ranbaxy Laboratories, recorded forth quarter profit of 9.6 billion rupees, beating streets estimate and overtaking the loss of 7.6 billion rupees during the same period last year.

Last year sales were 15.6 billion rupees which for current year jumped to 24.9 billion recording 65 percent increase.

"Solid growth in key geographies, along with optimal delivery value from first-to-file opportunities in the United States, ensured that we achieved yet another quarter of strong operational performance," said Atul Sobti, the company's chief executive.

Ranbaxy Swings to Profits in Q4

Ranbaxy Swings to Profits in Q4Ranbaxy Laboratories today swung to a consolidated quarterly profit after tax of Rs 262 crore for the quarter ended December, 2009, triggered by the launch of its own copy of a blockbuster drug in the U. S., and forecast strong growth this year from new products.

Ranbaxy exits Joint Venture with Nihon Pharmaceuticals

ranbaxyLeading pharmaceutical company Ranbaxy Laboratories has announced to sell its 50 per cent stake in its Japanese joint venture with Nihon Pharmaceutical Industry (NPI) without divulging the financial details of the deal. However, media reports claim that the buyer Nippon Chemiphar, founded in 1950, would pay $18 million for the 50 per cent stake.

Ranbaxy Laboratories gets USFDA nod for Glycopyrrolate Tablets

Ranbaxy Laboratories gets USFDA nod for Glycopyrrolate TabletsRanbaxy Laboratories, India's largest pharmaceutical company, has finally got approval from the U. S. Food and Drug Administration to manufacture and market Glycopyrrolate Tablets USP, 1 mg and 2 mg in the market.

Indian Market close higher; Ranbaxy, IFCI and LIC Housing Finance shine

SensexIndian markets closed above 15,000 level as buying was seen in major Banking, Metals and Capital Goods counters. Technical experts were expecting Indian markets to trade lower for the day as US markets closed lower on Monday and Asian stocks were seen lower during the start of session. However, markets surprised traders and started gaining momentum after first 30 minutes of trade.

Ranbaxy gets USFDA nod for migraine drug

Ranbaxy gets USFDA nod for migraine drugRanbaxy Laboratories, leading Indian drug manufacturer, has received US Food & Drug Administration's (USFDA) final approval to manufacture and sell Sumatriptan Succinate tablets.

The approval has been granted for tablets in potencies of 25 mg (base) and 50 mg (base).

Ranbaxy registers net loss of Rs 807 crore in Q4

Ranbaxy registers net loss of Rs 807 crore in Q4 India's largest pharmaceutical company Ranbaxy Laboratories clocked net loss of Rs 806.55 crore in the quarter ended December 2008 as against net profit of Rs 48.40 crore during the previous quarter ended December 2007.

In addition, the company's sales declined 2.00% to Rs 1012.72 crore in the quarter ended December 2008 as against Rs 1033.43 crore during the previous quarter ended December 2007.

Daiichi concludes acquisition process of Ranbaxy

Finally, Japan based drug maker Daiichi Sankyo has completed the acquisition process of Indian drug maker Ranbaxy Laboratories on Friday. The Japanese drug maker acquired remaining 11.4% stake for Rs 3,537.6 crore and its total stakes increased to 63.92%. 

Now, Daiichi has become the majority stake holder of the largest drug maker in the country. Singh family would still have some management roles in Ranbaxy. However, Ranbaxy would continue to work as an independent company.

Miscellaneous

Reliance Industries Purchase an Additional 0.68% Interest in EIH Ltd.

Reliance Industries Purchase an Additional 0.68% Interest in EIH Ltd.

Owner of Energy giant Reliance Industries, Mukesh Ambani has put in an extra 0.68% in EIH Ltd. With this, his total stake in the hotel chain has increased to 14.8%. In a filing to the Bombay Stock Exchange, EIH said that the shares were purchased from the market on Tuesday.

Shares of Reliance surged 0.3% at Rs. 939.3 in proportion to the Mumbai market at 1.26pm, while EIH shares witnessed a 4.5% rise at Rs. 150.2.

On Monday, Reliance was quoted saying that it is widening its horizon and has procured 14.12% stake in EIH for a sum of $217.5 million.

Bajaj Auto Records 55% Surge in Sales of Vehicles in August

Bajaj Auto Records 55% Surge in Sales of Vehicles in August

On Thursday, Bajaj Auto posted a 55% increase in its sales of vehicles. In the month of August, the Company recorded sales of 3,29,364 vehicles, compared to 2,13,072 units in the same month the year before.

Last month, 2,89,176 two wheelers were sold by Bajaj Auto, a big surge than 1,82,441 units, which were sold in August 2009. The Company’s cumulative sales of two wheelers for the time frame between April and August 2010 increased by 68% and were recorded at 1,397,348 units. The number was high from 833,235 units that were retailed during the same period last year.